Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues
AbstractRheumatoid arthritis (RA) is a polygenic and multifactorial syndrome. Many complex immunological and genetic interactions are involved in the final outcome of the clinical disease. Autoantibodies (rheumatoid factors, anti-citrullinated peptide/protein antibodies) are present in RA patients’ sera for a long time before the onset of clinical disease. Prior to arthritis onset, in the autoantibody response, epitope spreading, avidity maturation, and changes towards a pro-inflammatory Fc glycosylation phenotype occurs. Genetic association of epitope specific autoantibody responses and the induction of inflammation dependent and independent changes in the cartilage by pathogenic autoantibodies emphasize the crucial contribution of antibody-initiated inflammation in RA development. Targeting IgG by glyco-engineering, bacterial enzymes to specifically cleave IgG/alter N-linked Fc-glycans at Asn 297 or blocking the downstream effector pathways offers new avenues to develop novel therapeutics for arthritis treatment. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nandakumar, K.S. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. Int. J. Mol. Sci. 2018, 19, 677.
Nandakumar KS. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. International Journal of Molecular Sciences. 2018; 19(3):677.Chicago/Turabian Style
Nandakumar, Kutty S. 2018. "Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues." Int. J. Mol. Sci. 19, no. 3: 677.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.